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Development of sensory neuropathy 
in streptozotocin-induced diabetic mice
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ABSTRACT: Diabetic polyneuropathy is a major complication of diabetes and the most 
common cause of peripheral neuropathy. Sensory-dominant neuropathy is the most common 
type. We previously used streptozotocin (STZ)-induced diabetic ddY mice with sensory 
neuropathy to evaluate the therapeutic effects of vascular endothelial growth factor and 
placental growth factor isoforms. In this study, to characterize the development of diabetic 
sensory neuropathy, electrophysiological, behavioral, and histopathological studies were 
performed in these diabetic mice. A signiÞ cant difference in sensory conduction velocity in 
the tail nerve was observed between healthy and diabetic mice at 1 week after STZ injection. 
Diabetic mice developed hypoalgesia at 5 weeks after STZ injection. Axon area and myelin 
thickness of the myelinated Þ bers were increased in 17-week-old healthy mice compared 
with those in 8-week-old healthy mice. However, these increases were retarded in 17-week-
old diabetic mice. In unmyelinated Þ bers, axon area was signiÞ cantly reduced in 17-week-
old diabetic mice compared with 8- and 17-week-old healthy mice. These Þ ndings suggest 
that both impaired maturation of myelinated fibers and atrophy of unmyelinated fibers 
simultaneously occur in the early stage of diabetes in these mice. Our mouse model may be 
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